A Pharmaco-Economic Analyzis of Treating Severe Uncontrolled Child Asthma with Omalizumab — Actual Russian Clinical Practice Data
Background: Omalizumab is the first and yet the only biopreparation for asthma which combines high efficiency and high cost. The clinical-economic expediency of using omalizumab in asthmatic children has not been previously studied in Russia.Objective: Our aim was to evaluate the clinical and econom...
Saved in:
| Main Authors: | A. S. Kolbin, L. S. Namazova-Baranova, E. A. Vishneva, M. Y. Frolov, T. L. Galankin, A. A. Alekseeva, E. A. Dobrynina |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Union of pediatricians of Russia
2016-11-01
|
| Series: | Педиатрическая фармакология |
| Subjects: | |
| Online Access: | https://www.pedpharma.ru/jour/article/view/1440 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ECONOMIC ASPECTS OF APPLICATION OF THE RUSSIAN BIOSIMILAR OMALIZUMAB IN PATIENTS WITH ATOPIC BRONCHIAL ASTHMA OF MODERATE TO SEVERE CLINICAL COURSES
by: V. S. Krysanova, et al.
Published: (2021-08-01) -
Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients
by: A. Arrobas, et al.
Published: (2021-03-01) -
The Long-Term Omalizumab Therapy in Children with Severe Persistent Uncontrolled Asthma: Evaluation of the Outcomes According to the Data of the Hospital Patient Registry
by: Elena A. Vishneva, et al.
Published: (2018-05-01) -
Efficiency of Adding Omalizumab to Standard Therapy for Children with Recurrent Spontaneous Urticaria: Comparative Observational Study
by: Vera G. Kalugina, et al.
Published: (2020-08-01) -
PRIMARY RESULTS OF LONG-TERM DYNAMIC MONITORING OF CHILDREN WITH BRONCHIAL ASTHMA OF UNCONTROLLED SEVERE PERSISTENT COURSE
by: L. S. Namazova-Baranova, et al.
Published: (2017-02-01)